BioAsset

Insights / All articles

Research

The $30 Million Bet: How Valthos and AI Are Rewriting Biodefense

By Dmitry Vysotskiy, Founder & President at BioAsset · 4 slides

Valthos, a company that uses AI to identify and counter biological threats, has received $30 million in backing from the OpenAI Startup Fund along with Lux Capital and Founders Fund. The OpenAI Startup Fund is an investment vehicle associated with OpenAI, the maker of ChatGPT. Lux Capital and Founders Fund are both venture capital firms.

What Valthos does

Valthos is an applied biointelligence company. It specializes in identifying biological threats in real time, and it designs pathogen sensing, molecular modeling and countermeasures with AI systems that go head-to-head with a given threat.

Biodefense refers to the technologies, systems and materials used to detect, prevent and respond to biological threats, such as viruses, bacteria and other pathogens that can endanger public health or national security. Valthos develops AI-driven biointelligence systems designed to greatly reduce the time required to identify and counter those threats, enabling real-time detection and a rapid biomedical response.

Why investors are interested

The biodefense and biotechnology sector is growing rapidly, and the addition of advancing AI is attracting investors such as the OpenAI Startup Fund. Backing Valthos and its AI-enabled biodefense platform reflects OpenAI’s bold push into areas where AI meets national security and rapid biological threat response.

The forecasts point the same way. Data from Precedence Research (2025) show the global biodefense market growing to around $22.8 billion by 2030. The market for AI in biotechnology is charted rising every year from 2024 to 2034.

With the industry growing, OpenAI and its VC partners might be getting ahead of their competitors. The deal is also another example of a trend we have noted before: investment in biomedicine by venture capital and asset management firms keeps growing.

What to be aware of

Valthos claims that it will minimize these threats in real time with frontier AI. That is a great picture to paint, but Valthos will have to make sure it delivers on that picture with efficiency.

Competition is coming as well. Many big names are expected to enter biodefense, especially with AI emerging, and Valthos will have to prove its worth in order to survive and become a powerhouse in this part of biomedicine.

AI is still a double-edged sword to many. For as many good things as can be done with it, an equal number of negative exploitations may arise. In the coming years, the impact of AI in this field will become very clear.

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.